AGP Executive Report
Last update: 12 hours agoRett syndrome drug push: The EMA’s CHMP has issued a positive opinion for Neuren/Acadia’s DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome in adults and children aged 5+, moving the case to a European Commission decision. Cancer care update: The European Commission approved Merck’s KEYTRUDA + Padcev combo for resectable muscle-invasive bladder cancer patients who can’t receive cisplatin, based on KEYNOTE-905/EV-303 results. Breast cancer option: Gilead’s Trodelvy (sacituzumab govitecan) won EU marketing authorisation as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in eligible adults. Cross-border healthcare basics: A guide explains how cross-border healthcare works across Europe—who can use it, what costs are covered, and when prior authorisation is needed. Travel and access rules: A Blue Badge travel guide notes reciprocal parking arrangements that can apply in Liechtenstein and other countries. Border delays: EU’s Entry/Exit System is causing major airport queues, with some travellers facing delays of up to 4–6 hours. Public health and safety: Record heat is forcing school closures and shortened days in parts of Europe, as classrooms struggle without cooling.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
